MYC and diffuse large B-cell lymphoma: Well-timed combination BH3 mimetic therapy may be a promising strategy against diseases like DLBCL where oncoproteins (e.g. MYC, BCL6, and BCL-2) play roles in blocking the intrinsic apoptotic network through direct upregulation of BCL-2 family members and other cell death-related proteins [53, 54].